CD8A and non-small cell lung carcinoma: In contrast to a small study among NSCLC patients treated with nivolumab, that showed that low PD-1 to CD8 ratio was associated with DCB and progression-free survival (PFS), we found that high stromal infiltration of both PD-1+ and CD8+ immune cells was associated with DCB and OS.